Compare Equinix Inc (EQIX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Equinix Inc trades at $1,005.62 (market cap $100.85B), while State Street SPDR S&P Biotech ETF trades at $151.97. The key difference: Equinix Inc pays a 1.93% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| EQIX | XBI | |
|---|---|---|
Market Cap | $100.85B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $1.12K | $164.28 |
52-Week Low | $726.09 | $85.16 |
Enterprise Value | $121.14B | — |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,005.31, down 1.78% today, with a bearish technical signal despite strong analyst support. The company reported mixed Q1 2026 earnings with a slight miss on EPS expectations but maintains robust revenue growth and profitability. Recent partnerships with Cisco and NVIDIA position EQIX well for AI infrastructure demand, though high valuation ratios and negative cash flow trends present challenges.
The outlook remains cautiously optimistic with 74.5% analyst buy ratings and a $1,110 consensus price target suggesting 10% upside. Key risks include elevated debt levels, aggressive capital expenditure, and competitive pressures in the data center REIT sector. The stock offers exposure to digital infrastructure growth but requires monitoring of cash flow sustainability.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
